← SynDRA
IMD-0354
SynDRA canonical compound SYN0019068 — structure-anchored drug synonym record
| Clinical phase | Phase 1 |
|---|
| Primary target(s) | IKBKB |
|---|
| Mechanism of action | IKK inhibitor | NFkB pathway inhibitor |
|---|
All known targets
Mechanisms of action (all sources)
- IKBKB INHIBITOR
- Inhibitor of nuclear factor kappa B kinase beta subunit inhibitor
- IKK inhibitor
- NFkB pathway inhibitor
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- AAK1
- P2RX7
- PDGFRB
- PCYT1A
- PAK6
- PAK4
- PAK2
- PAK1
- PAICS
- P2RX4
- PEBP1
- P2RX3
- P2RX2
- P2RX1
- OPA1
- OGG1
- NUAK2
- NTRK1
- PDXK
- PGRMC1
- MAPK1
- POLK
- PRKAR2A
- PRKAG2
- PRKAG1
- PRKACG
- PRKACB
- PRKACA
- PRKAA1
- PLK4
- PHKG2
- PLK1
- PKN2
- PKN1
- PKMYT1
- PIP4K2C
- PIP4K2A
- PIM1
- NTHL1
- NQO2
Cross-references
Synonyms
- TCMDC-125465
- IMD-2560
- IMD-2560)
- I-kappaB kinase beta inhibitor (dermatological, atopic dermatitis/acne), Institute of Medicinal MolecularDesign
- I-kappaB kinase beta inhibitor (oral, rheumatoid arthritis/osteoporosis), IMMD
- IKK-beta inhibitor (dermatological, atopic dermatitis/acne), IMMD
- IL-6 release inhibitor (oral, rheumatoid arthritis/osteoporosis), IMMD
- BRD-K74305673
- IKK-2-inhibitor-V
- IMD0354
- RefChem:147935
- DTXCID50165739
- MFCD00218820
- C15H8ClF6NO2
- UNII-76145IS906
- Kinome_1864
- MLS006011200
- SCHEMBL129165
- orb1301039
- SCHEMBL29406220
- CHEBI:93310
- GLXC-06812
- HMS3229F11
- HMS3269F13
- HMS3413J21
- HMS3651D21
- HMS3677J21
- BDBM50430160
- EBC-70082
- IMD-0354?
- NSC800773
- NSC816638
- s2864
- AKOS017344958
- CCG-268447
- CS-4922
- NSC-800773
- NSC-816638
Look up IMD-0354 in the interactive SynDRA portal →